Cardiff Oncology Inc (NASDAQ: CRDF) kicked off on Monday, down -5.88% from the previous trading day, before settling in for the closing price of $5.61. Over the past 52 weeks, CRDF has traded in a range of $0.94-$6.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 9.26% over the past five years. While this was happening, its average annual earnings per share was recorded -4.78%. With a float of $41.07 million, this company’s outstanding shares have now reached $44.68 million.
Let’s look at the performance matrix of the company that is accounted for 32 employees.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 8.07%, while institutional ownership is 12.13%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 7.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.78% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Take a look at Cardiff Oncology Inc’s (CRDF) current performance indicators. Last quarter, stock had a quick ratio of 7.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 481.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ: CRDF) saw its 5-day average volume 0.74 million, a negative change from its year-to-date volume of 1.55 million. As of the previous 9 days, the stock’s Stochastic %D was 26.21%. Additionally, its Average True Range was 0.60.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 78.49%, which indicates a significant increase from 7.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.15% in the past 14 days, which was lower than the 117.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.78, while its 200-day Moving Average is $2.05. Nevertheless, the first resistance level for the watch stands at $5.55 in the near term. At $5.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.97. If the price goes on to break the first support level at $5.13, it is likely to go to the next support level at $4.97. The third support level lies at $4.71 if the price breaches the second support level.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
The company with the Market Capitalisation of 235.91 million has total of 44,677K Shares Outstanding. Its annual sales at the moment are 490 K in contrast with the sum of -41,440 K annual income. Company’s last quarter sales were recorded 160 K and last quarter income was -9,340 K.
